MRIN Earnings

MRIN reported its earnings on 2024-10-31, showcasing a revenue of 4.28M against an estimate of , resulting in a 0% surprise. The EPS was -0.71, surpassing the expected 0 by 0%. The stock experienced a 0.97% price change on the earnings day and a 1.46% change over the next five days, reflecting market reactions to the results.

Following MRIN's earnings announcement on 2024-10-31, the stock price moved by 0.97% on the day of the release. Over the subsequent five days, it saw a 1.46% change. Historically, MRIN's stock price tends to shift by an average of 7.47% in the 10 days leading up to earnings and -0.41% in the 10 days following, providing insight into potential market.

For , analysts estimate MRIN's annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MRIN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MRIN's stock price typically moves by 7.47% in the 10 days before its earnings and -0.41% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

Despite strategic partnerships and cost-cutting measures, the company faces declining revenues and significant operating losses. The cash balance is decreasing, raising liquidity concerns, and the restructuring costs further strain financial health. Although there are improvements in non-GAAP operating loss, the overall sentiment from the earnings call is negative due to uncertainties in revenue growth, economic factors, and potential regulatory risks. The market may react negatively to these factors over the next two weeks.